Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy

Neuromuscular Disorders

Volumn 12, Issue SUPPL., 2002, Pages

  Aartsma Rus, Annemieke ^a   Bremmer Bout, Mattie ^a   Janson, Anneke A M ^a   Den Dunnen, Johan T ^a   Van Ommen, Gert Jan B ^a   Van Deutekom, Judith C T ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antisense oligoribonucleotide; Duchenne muscular dystrophy; Exon skipping; Gene correction therapy

Indexed keywords

ANTISENSE OLIGORIBONUCLEOTIDE; NUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG;

CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE DELETION; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN CELL; MUSCLE CELL; PRIORITY JOURNAL;

BASE SEQUENCE; DYSTROPHIN; EXONS; GENE TARGETING; GENE THERAPY; HUMANS; MOLECULAR SEQUENCE DATA; MUSCULAR DYSTROPHY, DUCHENNE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0036823504     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(02)00086-X     Document Type: Conference Paper

References (27)

1. Hoffman E.P., Brown R.H. Jr, Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:1987;919-928.
2. Monaco A.P., Bertelson C.J., Liechti-Gallati S., Moser H., Kunkel L.M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 2:1988;90-95.
3. Koenig M., Beggs A.H., Moyer M., et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 45:1989;498-506.
4. Zubrzycka-Gaarn E.E., Bulman D.E., Karpati G., et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature. 333:1988;466-469.
5. Yoshida M., Ozawa E. Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem (Tokyo). 108:1990;748-752.
6. Ervasti J.M., Campbell K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell. 66:1991;1121-1131.
7. Koenig M., Monaco A.P., Kunkel L.M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 53:1988;219-226.
8. van Deutekom J.C., Floyd S.S., Booth D.K., et al. Implications of maturation for viral gene delivery to skeletal muscle. Neuromuscul Disord. 8:1998;135-148.
9. Mayeda A., Hayase Y., Inoue H., Ohtsuka E., Ohshima Y. Surveying cis-acting sequences of pre-mRNA by adding antisense 2′-O-methyl oligoribonucleotides to a splicing reaction. J Biochem (Tokyo). 108:1990;399-405.
10. Galderisi U., Cascino A., Giordano A. Antisense oligonucleotides as therapeutic agents. J Cell Physiol. 181:1999;251-257.
11. Baker B.F., Monia B.P. Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta. 1489:1999;3-18.
12. Kole R., Sazani P. Antisense effects in the cell nucleus: modification of splicing. Curr Opin Mol Ther. 3:2001;229-234.
13. Sicinski P., Geng Y., Ryder-Cook A.S., Barnard E.A., Darlison M.G., Barnard P.J. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 244:1989;1578-1580.
14. Dunckley M.G., Manoharan M., Villiet P., Eperon I.C., Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet. 7:1998;1083-1090.
15. Mann C.J., Honeyman K., Cheng A.J., et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA. 98:2001;42-47.
16. Wilton S.D., Lloyd F., Carville K., et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord. 9:1999;330-338.
17. Takeshima Y., Wada H., Yagi M., et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev. 23:2001;788-790.
18. Pramono Z.A., Takeshima Y., Alimsardjono H., Ishii A., Takeda S., Matsuo M. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun. 226:1996;445-449.
19. Watakabe A., Tanaka K., Shimura Y. The role of exon sequences in splice site selection. Genes Dev. 7:1993;407-418.
20. Tanaka K., Watakabe A., Shimura Y. Polypurine sequences within a downstream exon function as a splicing enhancer. Mol Cell Biol. 14:1994;1347-1354.
21. van Deutekom J.C., Bremmer-Bout M., Janson A.A., et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 10:2001;1547-1554.
22. Mathews D.H., Sabina J., Zuker M., Turner D.H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol. 288:1999;911-940.
23. Richler C., Yaffe D. The in vitro cultivation and differentiation capacities of myogenic cell lines. Dev Biol. 23:1970;1-22.
24. Surono A., Takeshima Y., Wibawa T., Pramono Z.A., Matsuo M. Six novel transcripts that remove a huge intron ranging from 250 to 800 kb are produced by alternative splicing of the 5′ region of the dystrophin gene in human skeletal muscle. Biochem Biophys Res Commun. 239:1997;895-899.
25. Shiga N., Takeshima Y., Sakamoto H., et al. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy. J Clin Invest. 100:1997;2204-2210.
26. Wells D.J., Wells K.E., Asante E.A., et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet. 4:1995;1245-1250.
27. Sironi M., Pozzoli U., Cagliani R., Comi G.P., Bardoni A., Bresolin N. Analysis of splicing parameters in the dystrophin gene: relevance for physiological and pathogenetic splicing mechanisms. Hum Genet. 109:2001;73-84.